logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Diclectin (doxylamine succinate and pyridoxine hydrochloride) for the treatment of nausea and vomiting in pregnancy

< Back

Diclectin (doxylamine succinate and pyridoxine hydrochloride) for the treatment of nausea and vomiting in pregnancy

Drugs

Pregnancy and Childbirth

March 2016


Nausea and vomiting in pregnancy, also known as morning sickness, is very common in early pregnancy. It is unpleasant, but usually stops by weeks 16 to 20 of pregnancy. Some women get a very severe form of nausea and vomiting called hyperemesis gravidarum, which can be very serious and needs specialist treatment in hospital.
There are currently no medications that are specifically licensed to treat nausea and vomiting in pregnancy, although medications licensed for other diseases can be used. Diclectin is a new drug that is designed to specifically treat nausea and vomiting in pregnancy.
Diclectin is being studied to see whether it improves nausea and vomiting in pregnancy and that it is safe to use for pregnant women. If diclectin is licensed for use in the UK, it could provide a new treatment for this unpleasant condition where other non-medical remedies have not worked.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts